tradingkey.logo
tradingkey.logo
Buscar

Nautilus Biotechnology Inc

NAUT
Añadir a la lista de seguimiento
1.730USD
-0.110-5.98%
Cierre 07/02, 13:00ETCotizaciones retrasadas 15 min
218.79MCap. mercado
PérdidaP/E TTM

Más Datos de Nautilus Biotechnology Inc Compañía

Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.

Información de Nautilus Biotechnology Inc

Símbolo de cotizaciónNAUT
Nombre de la empresaNautilus Biotechnology Inc
Fecha de salida a bolsaAug 07, 2020
Director ejecutivoPatel (Sujal)
Número de empleados155
Tipo de seguridadOrdinary Share
Fin del año fiscalAug 07
Dirección2701 Eastlake Ave East
CiudadSEATTLE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal98102
Teléfono12063332001
Sitio Webhttps://www.nautilus.bio/
Símbolo de cotizaciónNAUT
Fecha de salida a bolsaAug 07, 2020
Director ejecutivoPatel (Sujal)

Ejecutivos de Nautilus Biotechnology Inc

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Parag Mallick
Dr. Parag Mallick
Chief Scientist, Director
Chief Scientist, Director
20.69M
--
Mr. Farzad (Zod) Nazem
Mr. Farzad (Zod) Nazem
Independent Director
Independent Director
1.89M
--
Ms. Anna Mowry
Ms. Anna Mowry
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
85.50K
+11.70%
Mr. Kentaro (Ken) Suzuki
Mr. Kentaro (Ken) Suzuki
Chief Marketing Officer
Chief Marketing Officer
4.00K
--
Mr. Sujal Patel
Mr. Sujal Patel
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
--
--
Ms. Melissa B. Epperly
Ms. Melissa B. Epperly
Independent Director
Independent Director
--
--
Mr. Matthew S. (Matt) Mcilwain
Mr. Matthew S. (Matt) Mcilwain
Independent Director
Independent Director
--
--
Mr. Matthew L. Posard
Mr. Matthew L. Posard
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Karen Akinsanya
Ms. Karen Akinsanya
Independent Director
Independent Director
--
--
Mr. Nick Nelson
Mr. Nick Nelson
Chief Business Officer, Senior Vice President - Business Development
Chief Business Officer, Senior Vice President - Business Development
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Parag Mallick
Dr. Parag Mallick
Chief Scientist, Director
Chief Scientist, Director
20.69M
--
Mr. Farzad (Zod) Nazem
Mr. Farzad (Zod) Nazem
Independent Director
Independent Director
1.89M
--
Ms. Anna Mowry
Ms. Anna Mowry
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
85.50K
+11.70%
Mr. Kentaro (Ken) Suzuki
Mr. Kentaro (Ken) Suzuki
Chief Marketing Officer
Chief Marketing Officer
4.00K
--
Mr. Sujal Patel
Mr. Sujal Patel
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
--
--
Ms. Melissa B. Epperly
Ms. Melissa B. Epperly
Independent Director
Independent Director
--
--

Preguntas frecuentes

¿Quiénes son los cinco principales accionistas de Nautilus Biotechnology Inc?

Los cinco principales accionistas de Nautilus Biotechnology Inc son: Dr. Parag Mallick

¿Cuántas instituciones poseen acciones de Nautilus Biotechnology Inc (NAUT)?

A fecha de 2026Q1, 180 instituciones poseen acciones de Nautilus Biotechnology Inc, con un valor de mercado combinado de aproximadamente 60.30M, lo que representa el 47.66% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 1539418.00.